← Leaderboards
Hongwu Chen
University Of California At Davis
$9,989,556
Attributed
$9,989,556
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $985.6K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,989,556 · 6
VA$0 · 2
By mechanism
R01$9,989,556 · 6
I01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of California At Davis
Same institution · by research overlap
- Allen C Gao$13,767,104
- Pui-Kai Li$1,169,912
- Nagalakshmi Nadiminty$524,556
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingGene ExpressionInsightProgramsGenesGrowthOverexpressionTumorTumor GrowthProteinsChromatinMolecularCessation Of LifeCancer EtiologyComplexTherapeutic TargetMalignant NeoplasmsTherapy ResistantMalignant Neoplasm Of ProstateTranscription FactorNeoplasm MetastasisNuclear ReceptorsInnovationLink
Grant awards (42)
Targeting aberrant circadian regulator in advanced prostate cancer$368,288
R01 · FY2025 · CA · contact PI
Therapeutic targeting of a novel driver of prostate cancer progression.$0
I01 · FY2025 · VA · contact PI
Targeting aberrant circadian regulator in advanced prostate cancer$348,607
R01 · FY2024 · CA · contact PI
Therapeutic targeting of a novel driver of prostate cancer progression.$0
I01 · FY2024 · VA · contact PI
Therapeutic targeting of orphan NR in ER-negative breast cancer$411,021
R01 · FY2023 · CA · contact PI
Targeting aberrant circadian regulator in advanced prostate cancer$358,027
R01 · FY2023 · CA · contact PI
Therapeutic targeting of orphan NR in ER-negative breast cancer$442,178
R01 · FY2022 · CA · contact PI
Targeting aberrant circadian regulator in advanced prostate cancer$361,521
R01 · FY2022 · CA · contact PI
Therapeutic targeting of tumor metabolism in advanced prostate cancer$0
I01 · FY2022 · VA · contact PI
Therapeutic targeting of orphan NR in ER-negative breast cancer$451,202
R01 · FY2021 · CA · contact PI
Therapeutic targeting of tumor metabolism in advanced prostate cancer$0
I01 · FY2021 · VA · contact PI
Therapeutic targeting of orphan NR in ER-negative breast cancer$419,410
R01 · FY2020 · CA · contact PI
Targeting key orphan nuclear receptor in lethal prostate cancer$359,138
R01 · FY2020 · CA · contact PI
Therapeutic targeting of tumor metabolism in advanced prostate cancer$0
I01 · FY2020 · VA · contact PI
Therapeutic targeting of orphan NR in ER-negative breast cancer$419,410
R01 · FY2019 · CA · contact PI
Targeting key orphan nuclear receptor in lethal prostate cancer$348,363
R01 · FY2019 · CA · contact PI
Therapeutic targeting of tumor metabolism in advanced prostate cancer$0
I01 · FY2019 · VA · contact PI
Targeting key orphan nuclear receptor in lethal prostate cancer$359,138
R01 · FY2018 · CA · contact PI
Targeting key orphan nuclear receptor in lethal prostate cancer$359,138
R01 · FY2017 · CA · contact PI
Novel Epigenetic regulators in cancer therapeutic resistance and as new targets$0
I01 · FY2017 · VA · contact PI
Targeting key orphan nuclear receptor in lethal prostate cancer$358,756
R01 · FY2016 · CA · contact PI
Novel Epigenetic regulators in cancer therapeutic resistance and as new targets$0
I01 · FY2016 · VA · contact PI
Novel Epigenetic regulators in cancer therapeutic resistance and as new targets$0
I01 · FY2015 · VA · contact PI
Novel Epigenetic regulators in cancer therapeutic resistance and as new targets$0
I01 · FY2014 · VA · contact PI
Nuclear cofactors in hormone signaling$297,950
R01 · FY2012 · DK · contact PI
Nuclear cofactors in hormone signaling$297,950
R01 · FY2011 · DK · contact PI
AR signal mediators in prostate cancer$317,475
R01 · FY2010 · CA · contact PI
Nuclear cofactors in hormone signaling$300,960
R01 · FY2010 · DK · contact PI
Role of coactivators in cell growth and tumorigenesis$227,408
R01 · FY2010 · CA · contact PI
Nuclear cofactors in hormone signaling$139,750
R01 · FY2010 · DK · contact PI
AR signal mediators in prostate cancer$317,477
R01 · FY2009 · CA · contact PI
Nuclear cofactors in hormone signaling$304,000
R01 · FY2009 · DK · contact PI
Role of coactivators in cell growth and tumorigenesis$227,408
R01 · FY2009 · CA · contact PI
Nuclear cofactors in hormone signaling$304,000
R01 · FY2008 · DK · contact PI
Role of coactivators in cell growth and tumorigenesis$227,408
R01 · FY2008 · CA · contact PI
Role of coactivators in cell growth and tumorigenesis$227,119
R01 · FY2007 · CA · contact PI
Role of coactivators in cell growth and tumorigenesis$233,485
R01 · FY2006 · CA · contact PI
Protein acetylation as Mechanism of Hormone Signaling$226,246
R01 · FY2006 · DK · contact PI
Protein acetylation as Mechanism of Hormone Signaling$231,690
R01 · FY2005 · DK
Protein acetylation as Mechanism of Hormone Signaling$231,690
R01 · FY2004 · DK
Protein acetylation as Mechanism of Hormone Signaling$231,690
R01 · FY2003 · DK
Protein acetylation as Mechanism of Hormone Signaling$281,653
R01 · FY2002 · DK